<DOC>
	<DOC>NCT01484171</DOC>
	<brief_summary>To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).</brief_summary>
	<brief_title>HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1. Having signed informed consent 2. Diagnosis was based on the FrenchAmericanBritish (FAB) and WHO criteria. 3. Age ≥ 7 years old 4. Age ＜ 60 years old 1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>idarubicin</keyword>
	<keyword>Microtransplantation</keyword>
</DOC>